Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal presents in-depth content written by international experts in the study of resistance to anti-CD20 antibodies and approaches for their reversal. Anti-CD20 antibodies are used to achieve B cell depletion and are developed to treat B cell proliferative disorders, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia. In the past two decades, anti-CD20 antibodies have revolutionized the treatment of all B cell malignancies, however, there are patients that fail to respond to initial therapy or relapse sooner. This book explores new and existing avenues surrounding Anti-CD20 antibodies.
In recent years, several next-generation anti-CD20 therapies have been developed but predicting and reversing resistance is still a challenging task. These areas are being actively studied as they represent a potential to improve anti-CD20 therapies and are discussed thoroughly in the book.
It is a valuable resource for researchers, students and member of the biomedical and medical fields who want to learn more about resistance to anti-CD20 antibodies and their reversal.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Table of Contents
- Therapeutic antibodies against cancer A step toward the treatment
- Anti-CD20 antibody treatment for B-cell malignancies
- Anti-CD20 antibody treatment for diffuse large B cell lymphoma: Genetic alterations and signaling pathways
- Non-Hodgkin's lymphoma treated with anti-CD20 antibody-based immunochemotherapy
- Targeted therapies for follicular lymphoma
- Treatment of relapsed follicular lymphoma
- New monoclonal antibodies for the treatment of acute lymphoblastic leukemia
- Clinical relevance and therapeutic implications of CD20 expression in Hodgkin's lymphoma
- Therapeutic options for rituximab-resistant patients
- Mechanisms of resistance to anti-CD20 antibodies in lymphoid malignancies
- Kinetic exclusion assay using cellular membranes for affinity determination of anti-CD20 antibody
- Clinical efficacy of anti-CD20 antibodies in autoimmune diseases
- B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis
- Anti-CD20 antibodies in glomerular disease, their resistance and reversal approaches
- Adverse events following rituximab therapy in pemphigus patients
- Immune monitoring of patients treated with anti-CD20 therapeutic monoclonals for autoimmune disorders
- Clinical efficacy of anti-CD20 antibodies in neurological and neuromuscular diseases
- Highlights and perspectives by the contributors of the volume (resistance to anti-CD20 antibodies and approaches for their reversals) edited by Dr. William C.S. Cho
